Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer - Takeaways - MDSpire

Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer

  • By

  • Ryan D. Chow

  • John Rothen

  • Jessica B. Long

  • Pamela R. Soulos

  • Xiao Wang

  • Ronac Mamtani

  • Shuangge Ma

  • Natalia Kunst

  • Michaela A. Dinan

  • Cary P. Gross

  • May 27, 2026

  • 0 min

Share

  • 1

    Medicare issued a national coverage determination for broad genomic profiling (BGP) testing for metastatic cancer in 2018.

  • 2

    Despite increased BGP use, it remains underused due to barriers including payer policies and geographic variations in health systems.

  • 3

    Medicare Advantage (MA) plans are associated with lower chemotherapy costs but may delay treatment initiation for metastatic lung cancer.

  • 4

    Geographic variation significantly affects cancer treatment decisions, with 24% to 48% of differences attributed to region rather than patient factors.

  • 5

    The study analyzed BGP use among Medicare beneficiaries with metastatic cancer from 2020 to 2022, focusing on payer type and geographic variation.

Original Source(s)

Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer

  • by Ryan D. Chow, John Rothen, Jessica B. Long, Pamela R. Soulos, Xiao Wang, Ronac Mamtani, Shuangge Ma, Natalia Kunst, Michaela A. Dinan, Cary P. Gross

  • May 27, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report